Alkahest, Inc.
Alkahest, a subsidiary of Grifols, is a research and drug discovery company focused on plasma science to develop transformative therapies for age-related diseases. They leverage advanced technology, artificial intelligence, and extensive plasma protein expertise to identify early biomarkers and develop therapeutics. Their initial focus is on diseases such as Parkinson's Disease, Alzheimer's, and Age-Related Macular Degeneration, aiming to detect early biological signals and create innovative treatments.
Industries
Nr. of Employees
medium (51-250)
Alkahest, Inc.
125 Shoreway Road, Suite D, San Carlos, CA 94070
Patents
Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases
US-11957671-B2
View DetailsMethods and compositions for treating retina-associated disease using CCR3-inhibitors
US-11951102-B2
View DetailsMethods of inducing liver regeneration by administering a plasma protein fraction
US-11660316-B2
View Details
Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases
US-11957671-B2
View DetailsMethods and compositions for treating retina-associated disease using CCR3-inhibitors
US-11951102-B2
View DetailsMethods of inducing liver regeneration by administering a plasma protein fraction
US-11660316-B2
View DetailsProducts
Plasma-derived therapeutic candidate for Parkinson's disease
Therapeutic program derived from plasma protein biology aiming to treat Parkinson's disease and cognitive impairment using targets identified from age-associated plasma factors.
Plasma-derived therapeutic candidates for Alzheimer's disease
Programs to develop therapeutics for mild-to-moderate and severe Alzheimer's disease based on modulation of age-associated plasma proteins.
Therapeutic candidate for age-related macular degeneration (wet AMD)
Program focused on developing a therapeutic intervention for wet age-related macular degeneration informed by plasma protein biology.
Plasma-derived therapeutic candidate for Parkinson's disease
Therapeutic program derived from plasma protein biology aiming to treat Parkinson's disease and cognitive impairment using targets identified from age-associated plasma factors.
Plasma-derived therapeutic candidates for Alzheimer's disease
Programs to develop therapeutics for mild-to-moderate and severe Alzheimer's disease based on modulation of age-associated plasma proteins.
Therapeutic candidate for age-related macular degeneration (wet AMD)
Program focused on developing a therapeutic intervention for wet age-related macular degeneration informed by plasma protein biology.
Services
End-to-end profiling of plasma using proteomics, lipidomics and metabolomics, combined with integrative multiomics and machine learning to discover and prioritize disease biomarkers.
Large-scale retrospective analysis of longitudinal plasma samples focused on Parkinson's disease to detect pre-diagnostic biological signals and inform diagnostic or therapeutic development.
Annotation of clinical data and application of computational methods to integrate real-world health records with omics datasets for translational insights.
End-to-end profiling of plasma using proteomics, lipidomics and metabolomics, combined with integrative multiomics and machine learning to discover and prioritize disease biomarkers.
Large-scale retrospective analysis of longitudinal plasma samples focused on Parkinson's disease to detect pre-diagnostic biological signals and inform diagnostic or therapeutic development.
Annotation of clinical data and application of computational methods to integrate real-world health records with omics datasets for translational insights.
Expertise Areas
- Plasma proteomics
- Biomarker discovery from longitudinal cohorts
- Multiomics integration
- Real-world data analytics
Key Technologies
- Mass spectrometry-based proteomics
- Affinity-based proteomic platforms
- Lipidomics
- Metabolomics